Zanubrutinib Plus Venetoclax Generates 100% ORR in Treatment-Naive Del17p/TP53+ CLL/SLL
Treatment with the combination of zanubrutinib (Brukinsa) and venetoclax (Venclexta) led to an overall response rate (ORR) of 100% in patients with treatment-naive chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) harboring 17p …